Emory/Morehouse School of Medicine i2b2 Available for Special Population Study Feasibility
i2b2 is an easy-to-use website to query Emory Healthcare and Morehouse Healthcare electronic health record data for patient counts and aggregate information operated by the Georgia Clinical & Translational Science Alliance (Georgia CTSA). It can be the first step to determine study feasibility to recruit a special population. Researchers can use i2b2 to determine how many patients are in the health systems who meet their particular study criteria (age, disease status, etc.) who can be recruited for their studies. This is especially helpful for studies focusing on a rare disease or a specific lab test result.
This system gathers information on patients from electronic health records and lab results. It cleans and anonymizes the data, which can then be queried by a user of the system.
Prior to i2b2 this process was time consuming for researchers and their teams and became complicated when data came from a variety of sources, all supported by different vendors or hosted on separate computer hardware.
Morehouse School of Medicine (MSM) is another partner institution with access to i2b2.
Both Emory and MSM’s access and links may be protected against each institution firewall. Submit a request if you would like to access i2b2 but are having issues.
The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners – MSM, Georgia Tech, and UGA – to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide.
Georgia CTSA is one of nearly 60 in a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences (NCATS) and the National Institutes of Health’s Clinical and Translational Science Awards, shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts, and train the next generation of clinical investigators.